×
About 2,005 results

ALLMedicine™ Cardiovascular Risk Reduction Center

Research & Reviews  881 results

Investigating changes in disease activity as a mediator of cardiovascular risk reductio...
https://doi.org/10.1136/annrheumdis-2021-220125
Annals of the Rheumatic Diseases; Johnson TM, Sayles HR et. al.

May 29th, 2021 - Examine the association of methotrexate (MTX) use with cardiovascular disease (CVD) in rheumatoid arthritis (RA) using marginal structural models (MSM) and determine if CVD risk is mediated through modification of disease activity. We identified i...

Residual cardiovascular risk reduction guided by lifetime benefit estimation in patient...
https://doi.org/10.1093/eurjpc/zwab028
European Journal of Preventive Cardiology; Hageman SHJ, Dorresteijn JAN et. al.

May 19th, 2021 - To determine the (cost)-effectiveness of blood pressure lowering, lipid-lowering, and antithrombotic therapy guided by predicted lifetime benefit compared to risk factor levels in patients with symptomatic atherosclerotic disease. For all patients...

Comparative effectiveness of team-based care with a clinical decision support system ve...
https://doi.org/10.1016/j.ahj.2021.04.009
American Heart Journal; Shi X, He J et. al.

May 6th, 2021 - Diabetes has become a major public health challenge worldwide, especially in low- and middle-income countries (LMICs). Uncontrolled hyperglycemia, hypertension, and dyslipidemia major risk factors for all-cause mortality and cardiovascular disease...

Comparative Effectiveness of Behavioral Interventions for Cardiovascular Risk Reduction...
https://doi.org/10.1097/JCN.0000000000000806
The Journal of Cardiovascular Nursing; Estrada LV, Solano J et. al.

May 3rd, 2021 - Latinos, the fastest growing ethnic minority group in the United States, are at a high risk for cardiovascular disease (CVD). However, little is known about effective strategies to reduce CVD risk in this population. The aim of this study was to s...

The role of icosapent ethyl in cardiovascular risk reduction.
https://doi.org/10.1097/HCO.0000000000000873
Current Opinion in Cardiology; Goldenberg RM, Cheng AYY et. al.

Apr 30th, 2021 - Elevated levels of triglycerides, independent of low-density lipoprotein cholesterol (LDL-C) levels and statin therapy, are associated with heightened cardiovascular risk. Mixed omega-3 fatty acid formulations, which contain varying amounts of doc...

see more →

Guidelines  55 results

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545583
Journal of the American College of Cardiology; Das SR, Everett BM et. al.

Aug 10th, 2020 - 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.|2020|Das SR,Everett BM,Birtcher KK,Brown...

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
http://www.onlinejacc.org/content/early/2019/03/07/j.jacc.2019.03.010
Journal of the American College of Cardiology;

Mar 16th, 2019 - Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1- 1–S1-3). In the United States, it is also the le...

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext

Feb 1st, 2019 - Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large sta...

Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events
https://jamanetwork.com/journals/jama/article-abstract/2721178
Zheng,S.,et al

Jan 21st, 2019 - Question: What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease? Findings: In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, a...

Evidence of CV benefits of Mediterranean diet growing
https://www.healio.com/cardiology/chd-prevention/news/online/%7B51d6ca5b-5a70-4e7e-ae7b-84b411d0fd62%7D/evidence-of-cv-benefits-of-mediterranean-diet-growing

Jan 5th, 2019 - After the holidays, often as part of a New Year’s resolution, it is common for people to think about changing to a healthier diet. One option is the Mediterranean diet, which was recently named by U.S. News & World Report as the top overall diet, ...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  973 results

Investigating changes in disease activity as a mediator of cardiovascular risk reductio...
https://doi.org/10.1136/annrheumdis-2021-220125
Annals of the Rheumatic Diseases; Johnson TM, Sayles HR et. al.

May 29th, 2021 - Examine the association of methotrexate (MTX) use with cardiovascular disease (CVD) in rheumatoid arthritis (RA) using marginal structural models (MSM) and determine if CVD risk is mediated through modification of disease activity. We identified i...

Residual cardiovascular risk reduction guided by lifetime benefit estimation in patient...
https://doi.org/10.1093/eurjpc/zwab028
European Journal of Preventive Cardiology; Hageman SHJ, Dorresteijn JAN et. al.

May 19th, 2021 - To determine the (cost)-effectiveness of blood pressure lowering, lipid-lowering, and antithrombotic therapy guided by predicted lifetime benefit compared to risk factor levels in patients with symptomatic atherosclerotic disease. For all patients...

Comparative effectiveness of team-based care with a clinical decision support system ve...
https://doi.org/10.1016/j.ahj.2021.04.009
American Heart Journal; Shi X, He J et. al.

May 6th, 2021 - Diabetes has become a major public health challenge worldwide, especially in low- and middle-income countries (LMICs). Uncontrolled hyperglycemia, hypertension, and dyslipidemia major risk factors for all-cause mortality and cardiovascular disease...

Comparative Effectiveness of Behavioral Interventions for Cardiovascular Risk Reduction...
https://doi.org/10.1097/JCN.0000000000000806
The Journal of Cardiovascular Nursing; Estrada LV, Solano J et. al.

May 3rd, 2021 - Latinos, the fastest growing ethnic minority group in the United States, are at a high risk for cardiovascular disease (CVD). However, little is known about effective strategies to reduce CVD risk in this population. The aim of this study was to s...

The role of icosapent ethyl in cardiovascular risk reduction.
https://doi.org/10.1097/HCO.0000000000000873
Current Opinion in Cardiology; Goldenberg RM, Cheng AYY et. al.

Apr 30th, 2021 - Elevated levels of triglycerides, independent of low-density lipoprotein cholesterol (LDL-C) levels and statin therapy, are associated with heightened cardiovascular risk. Mixed omega-3 fatty acid formulations, which contain varying amounts of doc...

see more →

News  93 results

How Real-world Data Augments What We Know About SGLT-2 Inhibitors for Cardiovascular Risk Reduction
https://www.medscape.com/viewarticle/937947

Oct 11th, 2020 - Multiple clinical trials demonstrate the efficacy of sodium-glucose co-transporter-2 (SGLT-2) inhibitors to reduce cardiovascular events in persons with diabetes.[1,2,3,4] Use of these agents has been associated with consistent reductions in the c...

2020 ADA Standards: A 'New Concept' in Treating T2D
https://www.medscape.com/viewarticle/924308

Feb 27th, 2020 - This transcript has been edited for clarity. Today I'm going to continue my overview of the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes. Pharmacologic approaches to the management of glycemia in patients with typ...

New Vascepa Approval Opens Up Treatment to Millions
https://www.staging.medscape.com/viewarticle/922865

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

New Vascepa Approval Opens Up Treatment to Millions
https://www.medscape.com/viewarticle/922865

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

Icosapent ethyl approved for cardiovascular risk reduction
https://www.mdedge.com/emergencymedicine/article/214314/lipid-disorders/icosapent-ethyl-approved-cardiovascular-risk?channel=39313
Catherine Hackett

Dec 13th, 2019 - Icosapent ethyl (Vascepa) has gained an indication from the Food and Drug Administration for reduction of cardiovascular events in patients with high triglycerides who are at high risk for cardiovascular events. Olivier Le Moal/Getty Images It is.

see more →